A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers
Primary Purpose
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Radiolabelled GSK189075
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring metabolite profiling, excretion,, radioactivity,, pharmacokinetic,, mass balance,
Eligibility Criteria
Inclusion Criteria:
- Are a healthy, non-smoking male.
- Are 30 to 55 years old, inclusive.
- Have a Body Mass Index (BMI) between 19-30 kg/m2, inclusive; and a body weight >110 lbs.
- Have a history of regular bowel movements (at least 4 times per week).
- Are willing and able to provide written informed consent before the start of any study-related procedures.
Exclusion Criteria:
- Have any significant laboratory abnormality or history of liver or kidney disease.
- Have any significant abnormality in your electrocardiograms (ECG) which are recordings of your heart rhythm.
- Have a current condition(s) that alters normal gastrointestinal (GI) function (such as constipation or removal of your gallbladder).
- Have an illness that requires treatment by a physician in the 30 days before screening or a fever and illness in the 5 days before dosing.
- Have blood pressure that is outside the normal range.
- Have a resting pulse rate that is outside the normal range.
- Have had surgery within 3 months before screening, unless approved by the GSK medical monitor.
- Have a drug allergy which the investigator feels would make it unsafe for you to participate in the study.
- Have a history of or current abuse of alcohol.
- Have a history of or current use of illicit drugs, or a positive drug screen.
- Have used tobacco products within 3 months prior to screening or have a positive cotinine test result.
- Are unable to refrain from foods or beverages containing coffee, tea, or chocolate for 72 hours before dosing with study drug and until 24 hours after dose.
- Have a positive test for human immunodeficiency virus (HIV) antibody or hepatitis B surface antigen or hepatitis C antibody.
- Have taken prescription or non-prescription drugs, including vitamins, herbal products, or plant-derived supplements (including St John's Wort) within 14 days (or less than 5 half-lives) before the first dose of study medication, unless approved by the GSK medical monitor
- Have participated in an investigational drug study within the 30 days before screening, or participated within the last 12 months in a study with another radio labeled drug product.
- Have a total radiation exposure from the previous 3-year period that is over 10 mSv (either from your work or through participation in other research studies). Clinical (therapeutic or diagnostic) exposure will not be included.
- Have donated blood (450 mL or more) within the previous 12 weeks.
- Are in an occupation which requires monitoring for radiation exposure, nuclear medicine procedures or have had excessive x-rays within the past 12 months.
- Are not able to follow the study directions.
Sites / Locations
- GSK Investigational Site
Outcomes
Primary Outcome Measures
Laboratory tests to determine the amount of radiolabelled drug that is found in blood, urine, and feces. Blood samples at Days 1-5.
Urine & Fecal collection at Day -1 & days 1-5.
Secondary Outcome Measures
Adverse events (AEs), vital signs, ECGs and clinical laboratory assessments at each day for up to 10 days
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00501683
Brief Title
A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers
Official Title
A Mass Balance Study to Investigate the Metabolic Disposition of a 400 mg Single, Oral Dose of GSK189075 in Healthy Male Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
February 2011
Overall Recruitment Status
Completed
Study Start Date
November 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will look at the relative amounts of GSK189075 that are found in samples of blood, urine, and feces of healthy male volunteers. Results of the study will be used to understand how the drug is converted in the body and how it is eliminated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Keywords
metabolite profiling, excretion,, radioactivity,, pharmacokinetic,, mass balance,
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
8 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Radiolabelled GSK189075
Primary Outcome Measure Information:
Title
Laboratory tests to determine the amount of radiolabelled drug that is found in blood, urine, and feces. Blood samples at Days 1-5.
Time Frame
at Days 1-5.
Title
Urine & Fecal collection at Day -1 & days 1-5.
Time Frame
at Day -1 & days 1-5.
Secondary Outcome Measure Information:
Title
Adverse events (AEs), vital signs, ECGs and clinical laboratory assessments at each day for up to 10 days
Time Frame
at each day for up to 10 days
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Are a healthy, non-smoking male.
Are 30 to 55 years old, inclusive.
Have a Body Mass Index (BMI) between 19-30 kg/m2, inclusive; and a body weight >110 lbs.
Have a history of regular bowel movements (at least 4 times per week).
Are willing and able to provide written informed consent before the start of any study-related procedures.
Exclusion Criteria:
Have any significant laboratory abnormality or history of liver or kidney disease.
Have any significant abnormality in your electrocardiograms (ECG) which are recordings of your heart rhythm.
Have a current condition(s) that alters normal gastrointestinal (GI) function (such as constipation or removal of your gallbladder).
Have an illness that requires treatment by a physician in the 30 days before screening or a fever and illness in the 5 days before dosing.
Have blood pressure that is outside the normal range.
Have a resting pulse rate that is outside the normal range.
Have had surgery within 3 months before screening, unless approved by the GSK medical monitor.
Have a drug allergy which the investigator feels would make it unsafe for you to participate in the study.
Have a history of or current abuse of alcohol.
Have a history of or current use of illicit drugs, or a positive drug screen.
Have used tobacco products within 3 months prior to screening or have a positive cotinine test result.
Are unable to refrain from foods or beverages containing coffee, tea, or chocolate for 72 hours before dosing with study drug and until 24 hours after dose.
Have a positive test for human immunodeficiency virus (HIV) antibody or hepatitis B surface antigen or hepatitis C antibody.
Have taken prescription or non-prescription drugs, including vitamins, herbal products, or plant-derived supplements (including St John's Wort) within 14 days (or less than 5 half-lives) before the first dose of study medication, unless approved by the GSK medical monitor
Have participated in an investigational drug study within the 30 days before screening, or participated within the last 12 months in a study with another radio labeled drug product.
Have a total radiation exposure from the previous 3-year period that is over 10 mSv (either from your work or through participation in other research studies). Clinical (therapeutic or diagnostic) exposure will not be included.
Have donated blood (450 mL or more) within the previous 12 weeks.
Are in an occupation which requires monitoring for radiation exposure, nuclear medicine procedures or have had excessive x-rays within the past 12 months.
Are not able to follow the study directions.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53704
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers
We'll reach out to this number within 24 hrs